Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Acne Vulgaris · Pruritus · VYNE

VYNE Therapeutics

VYNE Therapeutics clinical programs — 19 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
520 U.S. Highway 22, Suite 204, Bridgewater, NJ 08807, US HQ
2003 Founded
47 Employees
Public company Type
VYNE · NYSE Ticker
Company details
Status
Public
HQ
520 U.S. Highway 22, Suite 204, Bridgewater, NJ 08807, US
Founded
2003
Employees
47
Programs
30
Drugs
16
Patents
7
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

VYNE Therapeutics projects

19 ClinicalTrials.gov programs sponsored by VYNE Therapeutics.

VYNE Therapeutics has 19 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

19 programs

Clinical programs

  1. 5 mg Serlopitant Tablets

    VYNE Therapeutics

    Refractory Chronic Cough

    phase 2 small molecule completed

    1 trial

  2. ARK-E021 5%

    VYNE Therapeutics

    Acne Vulgaris

    phase 2 small molecule completed

    1 trial

  3. Comparator: MK0594 5 mg/day

    VYNE Therapeutics

    Alcohol Dependence

    phase 2 small molecule terminated

    1 trial

  4. FCD105

    VYNE Therapeutics

    Acne Vulgaris

    phase 2 other completed

    1 trial

  5. FDX104 (4% Doxycycline)

    VYNE Therapeutics

    Rash Due to Epidermal Growth Factor Receptor Inhibitors

    phase 2 small molecule completed

    1 trial

  6. FMX-103 1.5%

    VYNE Therapeutics

    Rosacea

    phase 2 small molecule completed

    1 trial

  7. FMX114

    VYNE Therapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  8. MK0594

    VYNE Therapeutics

    Urinary Incontinence

    phase 2 small molecule completed

    1 trial

  9. Permethrin Foam 4%

    VYNE Therapeutics

    Scabies

    phase 2 small molecule completed

    1 trial

  10. Serlopitant

    VYNE Therapeutics

    Pruritus

    phase 2 small molecule terminated

    1 trial

  11. Serlopitant High Dose

    VYNE Therapeutics

    Pruritus

    phase 2 small molecule completed

    1 trial

  12. Serlopitant Tablet

    VYNE Therapeutics

    Epidermolysis Bullosa

    phase 2 small molecule completed

    1 trial

  13. Topical Minocycline Foam FXFM244

    VYNE Therapeutics

    Acne Vulgaris

    phase 2 small molecule completed

    1 trial

  14. Topical Minocycline Foam FXFM244

    VYNE Therapeutics

    Impetigo

    phase 2 small molecule completed

    1 trial

  15. Topical Minocycline Foam FXFM244

    VYNE Therapeutics

    Rosacea

    phase 2 small molecule terminated

    1 trial

  16. VPD-737

    VYNE Therapeutics

    Epidermolysis Bullosa

    phase 2 small molecule completed

    1 trial

  17. VPD-737

    VYNE Therapeutics

    Chronic Pruritus

    phase 2 small molecule completed

    1 trial

  18. VYN201 Gel

    VYNE Therapeutics

    Non-segmental Vitiligo

    phase 2 small molecule terminated

    1 trial

  19. serlopitant

    VYNE Therapeutics

    Prurigo Nodularis

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does VYNE Therapeutics have?

19 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.